These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24485094)

  • 1. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations.
    Stanczyk FZ; Archer DF
    Contraception; 2014 Apr; 89(4):242-52. PubMed ID: 24485094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations.
    Wilde MI; Balfour JA
    Drugs; 1995 Aug; 50(2):364-95. PubMed ID: 8521763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical comparison of monophasic oral contraceptive preparations of gestodene/ethinyl estradiol and desogestrel/ethinyl estradiol. Latin American Oral Contraceptive Study Group.
    Contraception; 1994 Sep; 50(3):201-14. PubMed ID: 7805371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol.
    Benagiano G
    Int J Fertil; 1989 Sep; 34 Suppl():31-9. PubMed ID: 2576255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene].
    Belaisch J; Hommais-loufrani B
    Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacology of newer progestogens.
    Kuhl H
    Drugs; 1996 Feb; 51(2):188-215. PubMed ID: 8808163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New progestins--clinical experiences: gestodene.
    Shoupe D
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1562-8. PubMed ID: 8178907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with a low-dose oral contraceptive containing gestodene.
    Düsterberg B; Brill K
    Adv Contracept; 1990 Dec; 6 Suppl():37-49; discussion 50. PubMed ID: 2291446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic aspects of the new low-dose oral contraceptives.
    Chez RA
    Int J Fertil; 1989 Sep; 34 Suppl():50-4. PubMed ID: 2576259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment.
    Stanczyk FZ; Archer DF; Bhavnani BR
    Contraception; 2013 Jun; 87(6):706-27. PubMed ID: 23375353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Third generation progestagens].
    Belaisch J; Eliakim V
    Contracept Fertil Sex (Paris); 1993 Apr; 21(4):287-93. PubMed ID: 12318226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metabolic impact of current estrogen-progestins and cardiovascular consequences].
    Gaspard U; Lambotte R
    Bull Mem Acad R Med Belg; 1991; 146(8-10):334-42; discussion 342-5. PubMed ID: 1815814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Safety, efficacy and control of the menstrual cycle by a monophasic oral contraceptive containing 75 mcg of gestodene and 30 mcg of ethynyl estradiol].
    Alvarado Zaldivar G; Ruiz Astorga R; Arenas Arenas M; Solis Carrera L; Rueda Cisneros D; Vázquez Arreola I
    Ginecol Obstet Mex; 1993 Oct; 61():299-303. PubMed ID: 8270225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?
    Odlind V; Milsom I; Persson I; Victor A
    Acta Obstet Gynecol Scand; 2002 Jun; 81(6):482-90. PubMed ID: 12047300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of a low-dose contraceptive--Femodene].
    Rachev E; Damianov L; Dukovski A; Katsarova M
    Akush Ginekol (Sofiia); 1995; 34(3):71-3. PubMed ID: 8787249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical overview of a new triphasic contraceptive containing gestodene.
    Christie T
    Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral contraception with a triphasic combination of gestodene and ethinyl estradiol: results of a multicenter clinical study.
    Skouby SO
    Int J Fertil; 1987; 32 Suppl():45-8. PubMed ID: 2906346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.